PR84626

SUZHOU, China, July 2, 2020 /PRNewswire=KYODO JBN/ --

CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M

in Series F financing following its US $90M Series E financing in January of

2020, in total, successfully completing an equity investment deal of nearly US

$140M within six months. The investors participated in the Series F financing

include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and

Watson Investment. Its existing investors including Passion Capital and

Yuanming Capital also participated. CEC Capital served as CF PharmTech's

exclusive financial advisor for both Series E and F financing.

Photo - https://photos.prnasia.com/prnh/20200701/2846325-1

There are nearly 300 million people suffering from asthma, chronic obstructive

pulmonary disease (COPD) or rhinitis in China. The occurrence of these chronic

diseases continues to rise. The State Council's Opinions on the Implementation

of Healthy China Actions issued by the State Council in July 2019 defined COPD

in China as a major chronic disease that seriously affects quality of life,

along with cancers, cardiovascular disease and diabetes. With this new round of

funding, CF Pharmtech is more poised than ever to provide respiratory disease

treatments for China and global market.

About CF PharmTech:

CF PharmTech is a fully integrated specialty pharmaceutical company dedicated

to providing affordable and high-quality respiratory drugs globally.  Managed

by a high caliber team with extensive experience in the industry, the company

focuses on the development of drugs for the treatment of respiratory diseases

in its state-of-the-art facilities. Learn more about CF PharmTech, visit

www.cfpharmtech.com.  

SOURCE: CF PharmTech, Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=366554

   Caption: CF PharmTech's manufacturing facility